investorscraft@gmail.com

Stock Analysis & ValuationShandong Pharmaceutical Glass Co., Ltd (600529.SS)

Professional Stock Screener
Previous Close
$20.45
Sector Valuation Confidence Level
Moderate
Valuation methodValue, $Upside, %
Artificial intelligence (AI)28.8741
Intrinsic value (DCF)11.62-43
Graham-Dodd Method8.67-58
Graham Formula15.35-25

Strategic Investment Analysis

Company Overview

Shandong Pharmaceutical Glass Co., Ltd is a leading Chinese manufacturer specializing in pharmaceutical glass packaging and butyl rubber products. Founded in 1970 and headquartered in Zibo, China, the company produces a comprehensive range of pharmaceutical-grade glass containers including molded injection vials, ampoules, tubular glass vials, and borosilicate glass products. The company serves critical needs in the pharmaceutical, food, and cosmetic packaging industries with products that require strict quality standards for drug safety and preservation. With expanding international reach, Shandong Pharmaceutical Glass exports to Europe, the United States, Russia, Japan, Korea, and Southeast Asia, positioning itself as a key player in the global pharmaceutical packaging supply chain. The company's integrated product portfolio, which includes prefilled syringes, rubber stoppers, and various closure systems, makes it an essential supplier to healthcare and consumer goods manufacturers worldwide.

Investment Summary

Shandong Pharmaceutical Glass presents a stable investment opportunity with defensive characteristics in the pharmaceutical packaging sector. The company demonstrates solid financial health with CNY 942.99 million net income on CNY 5.13 billion revenue, representing healthy margins. With a low beta of 0.298, the stock shows lower volatility than the broader market, appealing to risk-averse investors. The company's strong operating cash flow of CNY 1.17 billion supports its dividend payment of CNY 0.62 per share and ongoing capital expenditures. However, investors should monitor exposure to regulatory changes in pharmaceutical packaging standards and potential competition from alternative packaging materials. The company's international expansion provides growth opportunities but also exposes it to global economic fluctuations and trade dynamics.

Competitive Analysis

Shandong Pharmaceutical Glass maintains a strong competitive position in China's pharmaceutical packaging market through its specialized expertise in glass manufacturing and integrated product offerings. The company's competitive advantage stems from its decades of experience in pharmaceutical-grade glass production, which requires stringent quality control and regulatory compliance. Its vertical integration, producing both glass containers and complementary rubber stoppers, provides customers with complete packaging solutions and creates cross-selling opportunities. The company's export capabilities to regulated markets like Europe and the US demonstrate its ability to meet international quality standards, differentiating it from many domestic competitors. However, the company faces competition from both domestic Chinese manufacturers and multinational packaging companies with broader global footprints and more diversified product portfolios. The shift toward alternative materials like plastic and advanced polymers in pharmaceutical packaging represents a long-term competitive threat that requires ongoing innovation and adaptation. The company's focus on borosilicate glass, which offers superior chemical resistance and stability for sensitive pharmaceuticals, provides a technical barrier to entry for less specialized competitors.

Major Competitors

  • Nipro Pharma Packaging China Corporation (2012.HK): Nipro is a major multinational competitor with strong presence in pharmaceutical glass packaging across Asia. The company benefits from Japanese technological expertise and global distribution networks. However, as a foreign-operated company in China, it may face different regulatory and cost structures compared to domestic players like Shandong Pharmaceutical Glass.
  • China Sunsine Chemical Holdings Ltd (SGX: E86): While primarily a rubber chemicals producer, China Sunsine competes in the rubber components segment that complements pharmaceutical packaging. The company has strong rubber manufacturing capabilities but lacks the integrated glass packaging offerings that Shandong Pharmaceutical Glass provides, making it a partial competitor in specific product categories.
  • DuPont de Nemours, Inc. (DWDP): DuPont is a global materials science giant that produces advanced packaging materials including pharmaceutical packaging solutions. The company has superior R&D capabilities and global reach but focuses more on polymer-based solutions rather than traditional glass packaging. Its multinational presence creates both competitive pressure and potential partnership opportunities for Chinese manufacturers.
  • Huatong Pharmaceutical & Chemical Corporation (SGX: H02): Huatong produces pharmaceutical packaging materials and operates in similar market segments. The company competes in both domestic and export markets but may have different specialization focuses. Its competitive position relative to Shandong Pharmaceutical Glass depends on specific product lines and customer relationships.
  • Shanghai Dasheng Health Products Co., Ltd (601515.SS): Dasheng operates in pharmaceutical packaging and health products, creating overlap in certain market segments. The company benefits from its location in Shanghai, a major pharmaceutical hub, but may have different manufacturing capabilities and cost structures compared to Shandong-based competitors.
HomeMenuAccount